Sanofi Takes Dynavax Private

Sanofi decided the best post-holiday shopping spree isn’t in the mall — it’s in the vaccine aisle. The French drugmaker agreed to acquire Dynavax Technologies in an all-cash deal valued at about $2.2 billion, offering $15.50 per share via a cash tender offer for all outstanding shares. The deal is set to close in Q1 2026.

For Dynavax holders, the headline is clean and cheerful. With a 39% premium to Dynavax’s prior close (December 23, 2025), the deal price sent the stock sharply higher — basically the market’s way of gift-wrapping “congratulations” in green candles. And because it’s a straightforward cash offer, the story becomes less “will they, won’t they” and more “how tight does the spread get” as the calendar inches toward closing.

Strategically, Sanofi gets what it says it wants. For Sanofi, this acquisition means a bigger footprint in adult immunization, anchored by Dynavax’s marketed adult hepatitis B vaccine HEPLISAV-B, plus the early-stage shingles candidate Z-1018. In other words, Sanofi is buying a combo of “already selling” and “could be meaningful later,” which is corporate-speak for “we’d like growth that doesn’t require a miracle".

As a final stocking stuffer, Sanofi said it expects to fund the acquisition with available cash resources and that the deal won’t affect its 2025 financial outlook—a nice way of saying it wants the vaccines without the guidance drama. If this closes on schedule, Dynavax shareholders get a tidy exit, and Sanofi gets to walk into 2026 with a bigger adult-vaccine lineup — proof that sometimes the year’s most upbeat rally is simply called “cash.”

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726